Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure
prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of emtricitabine
(FTC)/tenofovir disoproxil fumarate (TDF), administered at sexually transmitted disease (STD)
clinics and a community health center in the United States.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination